The chemical defensive system in the pathobiology of idiopathic environment-associated diseases

Current Drug Metabolism

Volumn 10, Issue 8, 2009, Pages 914-931

  Korkina, L ^a,b   Scordo, M G ^c   Deeva, I ^a,b   Cesareo, E ^a   De Luca, C ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Catalase; CYPs; Genetic polymorphism; GSTs; Idiopathic environmental intolerances; Systemic lupus erythematosus; UGTs; Vitiligo

Indexed keywords

CATALASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYDROGEN PEROXIDE; PEROXIREDOXIN; PROTEOME; XENOBIOTIC AGENT;

BIOSENSOR; CHRONIC FATIGUE SYNDROME; DISEASE ASSOCIATION; DISEASE SEVERITY; ENVIRONMENTAL STRESS; ENZYME METABOLISM; EPIGENETICS; FIBROMYALGIA; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC CODE; GENETIC PREDISPOSITION; HUMAN; IMMUNITY; MULTIPLE CHEMICAL SENSITIVITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; VITILIGO; XENOBIOTIC METABOLISM;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; MULTIPLE CHEMICAL SENSITIVITY; OXIDATIVE STRESS; PEROXIDES; VITILIGO; XENOBIOTICS;

EID: 74249117600     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790274568     Document Type: Review

References (233)

1. Ariga, K.; Hill, J.P.; Ji, Q. Biomaterials and biofunctionality in layered macromolecular assemblies. Macromol. Biosci., 2008, 8(11), 981-990.
2. Ariga, K.; Ji, Q.; Hill, J.P.; Kawazoe, N.; Chen, G. Supramolecular approaches to biological therapy. Expert Opin. Biol. Ther., 2009, 9(3), 307-320.
3. Goldstone, J.V.; Hamdoun, A.; Cole, B.J.; Howard-Ashby, M.; Nebert, D.W.; Scally, M.; Dean, M.; Epel, D.; Hahn, M.E.; Stegeman, J.J. The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev. Biol., 2006, 300(1), 366-384.
4. Their, R.; Brüning, T.; Roos, P.H.; Rihs, H.P.; Golka, K.; Ko, Y.; Bolt, H.M. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int. J. Hyg. Environ. Health, 2003, 206(3), 149-171.
5. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
6. Cole, S.P.C.; Deeley, R.G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays, 1998, 20(11), 931-940.
7. Sarkadi, B.; Ozvegy-Laszka, C.; Nemet, K.; Varadi, A. ABCG2- A transporter for all seasons. FEBS Lett., 2004, 567(1), 116-120.
8. Denison, M.S.; Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 309-334.
9. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab., 2008, 9(2), 129-143.
10. Kluth, D.; Banning, A.; Paur, I.; Blomhoff, R.; Brigelius-Flohé, R. Modulation of pregnane X receptor- and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radic. Biol. Med., 2007, 42(3), 315-325.
11. Bock, K.W.; Köhle, C. Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucoronide transporters. Drug Metab. Rev., 2004, 36(3-4), 595-615.
12. Klaassen, C.D.; Slitt, A.L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab., 2005, 6(4), 309-328.
13. Nguyen, T.; Sherratt, P.J.; Pickett, C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 233-260.
14. Jaiswal, A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med., 2004, 36(10), 1199-1207.
15. Fadeel, B.; Orrenius, S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med., 2005, 258(6), 479-517.
16. Goth, L.; Rass, P.; Pay, A. Catalase enzyme mutations and their association with diseases. Mol. Diagn., 2004, 8(3), 141-149.
17. Scandalios, J.G. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz. J. Med. Biol. Res., 2005, 38(7), 995-1014.
18. Korkina, L.G.; Pastore, S.; De Luca, C.; Kostyuk, V. Metabolism of plant polyphenols in the skin: beneficial versus deleterious effects. Curr. Drug Metab., 2008, 9(8), 710-729.
19. Oesch, F.; Fabian, E.; Oesch-Bartlomowicz, B.; Werner, C.; Landsiedel, R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev., 2007, 39(4), 659-698.
20. Dixit, S.G.; Tirona, R.G.; Kim, R.B. Beyond CAR and PXR. Beyond CAR and PXR. Curr. Drug Metab., 2005, 6(4), 385-397.
21. Moore, D.D.; Kato, S.; Xie, W.; Mangelsdorf, D.J.; Schmidt, D.; Xiao, R.; Kliewer, S.A. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol. Rev., 2006, 58(4), 742-759.
22. Urquhart, B.L.; Tirona, R.G.; Kim, R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47(5), 566-578.
23. Zhou, C.; Tabb, M.M.; Nelson, E.L.; Grun, F.; Verma, S.; Sadatrafiei, A.; Lin, M.; Mallick, S.; Forman, B.M.; Thummel, K.E.; Blumberg, B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest., 2006, 116(8), 2280-2289.
24. Kawajiri, K.; Watanabe, J.; Eguchi, H.; Nakachi, K.; Kiyohara, C.; Hayashi, S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics, 1995, 5(3), 151-158.
25. Jenkins, C.M.; Cedars, A.; Gross, R.W. Eicosanoid signalling pathways in the heart. Cardiovasc Res., 2009, 82(2), 240-249.
26. Gunes, A.; Dahl, M-L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 2008, 9(5), 625-637.
27. Scordo, M.G.; Aklillu, E.; Yasar, U.; Dahl, M.L.; Spina, E.; Ingelman-Sundberg, M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 2001, 52(4), 447-450.
28. Scordo, M.G.; Caputi, A.P.; D'Arrigo, C.; Fava, G.; Spina, E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res., 2004, 50(2), 195-200.
29. Hellum, B.H.; Hu, Z.; Nilsen, O.G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharm. Toxicol., 2006, 100(1), 23-30.
30. Zanger, U.M.; Turpeinen, M.; Klein, K.; Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem., 2008, 392(6), 1093-1108.
31. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391.
32. van Schaik, R.H.; van der Heiden, I.P.; van den Anker, J.N.; Lindemans, J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem., 2002, 48(10), 1668-1671.
33. Ekhart, C.; Rodenhuis, S.; Smits, P.H.; Beijnen, J.H.; Huitema, A.D. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat. Rev., 2009, 35(1), 18-31.
34. Hayes, J.D.; Flanagan, J.U. Jowsey, I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 51-88.
35. Hayes, J.D.; Strange, R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 2000, 61(3),154-66.
36. Aceto, A.; Sacchetta, P.; Dragani, B.; Bucciarelli, T.; Angelucci, S.; Longo, V.; Gervasi, G.P.; Martini, F.; Di Ilio, C. Glutathione transferase isoenzymes in olfactory and respiratory epithelium of cattle. Biochem. Pharmacol., 1993, 46(12), 2127-2133.
37. Ben-Arie, N.; Khen, M.; Lancet, D. Glutathione S-transferases in rat olfactory epithelium: purification, molecular properties and odorant biotransformation. Biochem. J., 1993, 292(Pt 2), 379-384.
38. Cho, S.G.; Lee, Y.H.; Park, H.S.; Ryoo, K.; Kang, K.W.; Park, J.; Eom, S.J.; Kim, M.J.; Chang, T.S.; Choi, S.Y.; Shim, J.; Kim, Y.; Dong, M.S.; Lee, M.J.; Kim, S.G.; Ichijo, H.; Choi, E.J. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol. Chem., 2001, 276(16), 12749-12755.
39. Gilot, D.; Loyer, P.; Corlu, A.; Glaise, D.; Lagadic-Gossmann, D.; Atfi, A.; Morel, F.; Ichijo, H.; Guguen-Guillouzo, C. Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione Stransferase regulation. J. Biol. Chem., 2002, 277(51), 49220-49229.
40. Coles, B.F.; Kadlubar, F.F. Human alpha class glutathione Stransferases: genetic polymorphism; expression; and susceptibility to disease. Methods Enzymol., 2005, 401, 9-42.
41. Ahn, J.; Gammon, M.D.; Santella, R.M.; Gaudet, M.M.; Britton, J.A.; Teitelbaum, S.L.; Terry, M.B; Neugut, A.I.; Eng, S.M.; Zhang, Y.; Garza, C.; Ambrosone, C.B. Effects of glutathione Stransferase A1 (GSTA1) genotype and potential modifiers on breast cancer risk. Carcinogenesis, 2006, 9, 1876-1882.
42. Ross, V.L.; Board, P.G.; Webb, G.C. Chromosomal mapping of the human Mu class glutathione S-transferases to 1p13. Genomics, 1993, 18(1), 87-91.
43. Brockmöller, J.; Kerb, R.; Drakoulis, N.; Nitz, M.; Roots, I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res., 1993, 53(5), 1004-1011.
44. Seidegård, J.; Vorachek, W.R.; Pero, R.W.; Pearson, W.R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. U.S.A., 1988, 85(19), 7293-7297.
45. McLellan, R.A.; Oscarson, M.; Alexandrie, A.K.; Seidegård, J.; Evans, D.A.; Rannug, A.; Ingelman-Sundberg, M. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol. Pharmacol., 1997, 52(6), 958-965.
46. Bolt, H.M.; Their, R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr. Drug. Metab., 2006, 7(6), 613-628.
47. Ateş, N.A.; Tamer, L.; Ateş, C.; Ercan, B.; Elipek, T.; Ocal, K.; Camdeviren, H. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem. Genet., 2005, 43(3-4), 149-163.
48. Tamer, L.; Ates, N.A.; Ateş, C.; Ercan, B.; Elipek, T.; Yildirim, H.; Camdeviren, H.; Atik, U.; Aydin, S. Glutathione S-transferase M1, T1 and P1 genetic polymorphisms, cigarette smoking and gastric cancer risk. Cell. Biochem. Funct., 2005, 23(4), 267-272.
49. García-Closas, M.; Malats, N.; Silverman, D.; Dosemeci, M.; Kogevinas, M.; Hein, D. W.; Tardón, A.; Serra, C.; Carrato, A.; García-Closas, R.; Lloreta, J.; Castaño-Vinyals, G.; Yeager, M.; Welch, R.; Chanock, S.; Chatterjee, N.; Wacholder, S.; Samanic, C.; Torà, M.; Fernández, F.; Real, F.X.; Rothman, N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 2005, 366(9486), 649-659.
50. Kanetsky, P.A.; Holmes, R.; Walker, A.; Najarian, D.; Swoyer, J.; Guerry, D.; Halpern, A.; Rebbeck, T.R. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol. Biomarkers Prev., 2001, 10(5), 509-513.
51. Board, P.G.; Webb, G.C.; Coggan, M. Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14. Ann. Hum. Genet., 1989, 53(Pt 3), 205-213.
52. Ishikawa, T.; Ali-Osman, F. Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem., 1993, 268(27), 20116-20125.
53. Ali-Osman, F.; Akande, O.; Antoun, G.; Mao, J.X.; Buolamwini, J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem., 1997, 272(15), 10004-10012.
54. Srivastava, S.K.; Hu, X.; Xia, H.; Awasthi, S.; Amin, S.; Singh, S.V. Metabolic fate of glutathione conjugate of benzo[a]pyrene-(7R,8S)-diol (9S,10R)-epoxide in human liver. Arch. Biochem. Biophys., 1999, 371(2), 340-344.
55. Stoehlmacher, J.; Park, D.J.; Zhang, W.; Groshen, S.; Tsao-Wei, D.D.; Yu, M. C.; Lenz, H.J. Association between glutathione Stransferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst., 2002, 94(12), 936-942.
56. Lo, H.W.; Ali-Osman, F. Genetic polymorphism and function of glutathione S-transferases in tumour drug resistance. Curr. Opin. Pharmacol., 2007, 7(4), 367-374.
57. Okamura, T.; Singh, S.; Haystead, T.; Bigner, D.; Ali-Osman, F. EGFR phosphorylates Glutathione S-Transferase P1 (GSTP1), a novel downstream target, in human glioma cells. Proc. Annu. Meet. Am. Assoc. Cancer Res., 2006, 97, 80.
58. Pemble, S.; Schroeder, K.R.; Spencer, S.R.; Meyer, D.J.; Hallier, E.; Bolt, H.M.; Ketterer, B.; Taylor, J.B. Human glutathione Stransferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J., 1994, 300(Pt 1), 271-276.
59. Alexandrie, A.K.; Rannug, A.; Juronen, E.; Tasa, G.; Warholm, M. Detection and characterization of a novel functional polymorphism in the GSTT1 gene. Pharmacogenetics, 2002, 12(8), 613-619.
60. Coggan, M.; Whitbread, L.; Whittington, A.; Board, P. Structure and organization of the human theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex. Biochem. J., 1998, 334(Pt 3), 617-623.
61. Warholm, M.; Alexandrie, A.K.; Högberg, J., Sigvardsson, K.; Rannug, A. Polymorphic distribution of glutathione transferase activity with methyl chloride in human blood. Pharmacogenetics, 1994, 4(6), 307-311.
62. Wiebel, F.A.; Dommermuth, A.; Thier, R. The hereditary transmission of the glutathione transferase hGSTT1-1 conjugator phenotype in a large family. Pharmacogenetics, 1999, 9(2), 251-256.
63. Peter, H.; Deutschmann, S.; Reichel, C.; Hallier, E. (1989) Metabolism of methyl chloride by human erythrocytes. Arch. Toxicol., 1989, 63(5), 351-355.
64. Hallier, E.; Deutschmann, S.; Reichel, C.; Bolt, H.M.; Peter, H. A comparative investigation of the metabolism of methyl bromide and methyl iodide in human erythrocytes. Int. Arch. Occup. Environ. Health, 1990, 62(3), 221-225.
65. Andersen, M.E.; Clewell, H.J. 3rd; Gargas, M.L.; Smith, F.A.; Reitz, R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol., 1987, 87(2), 185-205.
66. Föst, U.; Hallier, E.; Ottenwälder, H.; Bolt, H.M.; Peter, H. Distribution of ethylene oxide in human blood and its implications for biomonitoring. Hum. Exp. Toxicol., 1991, 10(1), 25-31.
67. Ulmanen, I.; Peränen, J.; Tenhunen, J.; Tilgmann, C.; Karhunen, T.; Panula, P.; Bernasconi, L.; Aubry, J.P.; Lundström, K. Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells. Eur. J. Biochem., 1997, 243(1-2):452-459.
68. Lundstrom, K.; Tenhunen, J.; Tilgmann, C.; Karhunen, T.; Panula, P.; Ulmanen, I. Cloning, expression and structure of catechol-Omethyl transferase. Biochim., Biophys. Acta, 1995, 1251(1), 1-10.
69. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melén, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol-O-methyl transferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 1995, 34(13), 4202-4210.
70. Zhu B.T. On the mechanism of homocysteine pathophysiology and pathogenesis. A unifying hypothesis. Histol. Histopathol., 2002, 17(4), 1263-1291.
71. Zeisel, S.H. Genetic polymorphism in methyl-group metabolism and epigenetics: Lessons from humans and mouse models. Brain Res., 2008, 1237, 5-11.
72. Guillemette, C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenom. J., 2003, 3(3), 136-158.
73. Brierley, C.H. and Burchell, B. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays, 1993, 15(11), 749-754.
74. Lazard, D., Zupko, K., Poria, Y.; Nef, P.; Lazarovits, J.; Horn, S.; Khen, M.; Lancet, D. Odorant signal termination by olfactory UDP glucuronosyl transferase. Nature, 1991, 349(6312), 790-793.
75. Shen, Y.; Shen, H.M.; Shi, C.Y.; Ong, C.N. Benzene metabolites enhance reactive oxygen species generation in HL60 human leukemia cells. Hum. Exp. Toxicol., 1996, 15(5), 422-427.
76. Li, Y.; Kuppusamy, P.; Zweir, J.L.; Trush, M.A. Role of Cu/Znsuperoxide dismutase in xenobiotic activation. II. Biological effects resulting from the Cu/Zn-superoxide dismutase-accelerated oxidation of the benzene metabolite 1,4-hydroquinone. Mol. Pharmacol., 1996, 49(3), 412-421.
77. Tung, Y.T.; Wu, J.H.; Huang, C.C.; Peng, H.C.; Chen, Y.L.; Yang, S.C.; Chang, S.T. Protective effect of Acacia confusa bark extract and its active compound gallic acid against carbon tetrachlorideinduced chronic liver injury in rats. Food Chem. Toxicol., 2009, 47(6), 1385-1392.
78. Basu, S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology, 2003, 189(1-2), 113-127.
79. Lin, Z.; Luo, W.; Li, H.; Zhang, Y. The effect of endogenous formaldehyde on the rat aorta endothelial cells. Toxicol. Lett., 2005, 159(2), 134-143.
80. Saradha, B.; Vaithinathan, S.; Mathur, P.P. Single exposure to low dose of lindane causes transient decrease in testicular steroidogenesis in adult male Wistar rats. Toxicology, 2008, 244(2-3), 190-197.
81. Gupta, R.K.; Schuh, R.A.; Fiskum, G.; Flaws, J.A. Methoxychlor causes mitochondrial dysfunction and oxidative damage in the mouse ovary. Toxicol. Appl. Pharmacol., 2006, 216(3), 436-445.
82. Ponomarev, V.O.; Novikov, V.V.; Karnaukhov, A.V.; Ponomarev, O.A. Effect of a weak electromagnetic field on the rate of hydrogen peroxide production in aqueous solutions. Biofizika, 2008, 53(2), 197-204.
83. Schrader, M.; Fahimi, H.D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta, 2006, 1763(12), 1755-1766.
84. Bartosz, G. Reactive oxygen species: destroyers or messengers? Biochem. Pharmacol., 2009, 77(8), 1303-1315.
85. Brand, M.D.; Buckingham, J.A.; Esteves, T.C.; Green, K.; Lambert, A.J.; Miwa, S.; Murphy, M.P.; Gertz, M.; Fischer, F.; Wolters, D.; Steegborn, C. Activation of the lifespan regulator p66Shc through reversible disulfide bond formation. Proc. Natl. Acad. Sci. USA, 2008, 105(15), 5705-5709.
86. Gertz, M.; Fischer, F.; Wolters, D.; Steegborn, C. Activation of the lifespan regulator p66Shc through reversible disulfide bond formation. Proc. Natl. Acad. Sci. USA, 2008, 105(15), 5705-5709.
87. Liu, H.; Baliga, M.; Bigler, S.A.; Baliga, R. Role of cytochrome P450 2B1 in puromycin aminonucleoside-induced cytotoxicity to glomerular epithelial cells. Nephron. Exp. Nephrol., 2003, 94(1), 17-24.
88. Vasiliou, V.; Ziegler, T.L.; Bludeau, P.; Petersen, D.R.; Gonzalez, F.J.; Deitrich, R.A. CYP2E1 and catalase influence ethanol sensitivity in the central nervous system. Pharmacogenet. Genomics, 2006, 16(1), 51-58.
89. Sen, C.K.; Roy, S. Redox signals in wound healing. Biochim. Biophys. Acta, 2008, 1780(11), 1348-1361. [90] Roy, S.; Khanna, S.; Nallu, K.; Hunt, T.K.; Sen, C.K. Dermal wound healing is subject to redox control. Mol. Ther., 2006, 13(1), 211-220.
90. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 2007, 87(1), 245-313.
91. Boveris, A.; Oshino, N.; Chance, B. The cellular production of hydrogen peroxide. Biochem. J., 1972, 128(3), 617-630.
92. Coatrieux, C.; Sanson, M.; Negre-Salvayre, A.; Parini, A.; Hannun, Y.; Itohara, S.; Salvayre, R.; Auqe, N. MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic. Biol. Med., 2007, 43(1), 80-89.
93. McPhillips, K.; Janssen, W.J.; Ghosh, M.; Byrne, A.; Gardai, S.; Remigio, L.; Bratton, D.L.; Kang, J.L.; Henson, P. TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic phospholipase A2 and oxidant-dependent mechanisms. J. Immunol., 2007, 178(12), 8117-8126.
94. Anderson, T.E.; Schmid, A.; Baumgartner, E.; Cemeli-Carratala, M.H.; Brinkworth, J.; Wood, J.M. Oestrogenic compounds and oxidative stress in human sperm and lymphocytes in the Comet assay. Mutat. Res., 2003, 544(2-3), 173-178.
95. 2 generation in thyroid cells does not involve Rac1 activation. Eur. J. Endocrinol., 2005, 152(1), 127-133.
96. Leung, H.S.; Leung, F.P.; Yao, X.; Ko, W.H.; Chen, Z.Y.; Vanhoutte, P.M.; Huang, Y. Endothelial mediators of the acetylcholineinduced relaxation of the rat femoral artery. Pharmacol., 2006, 44(5), 299-308.
97. Schallreuter, K.U.; Wood, J.M.; Berger, J. Low catalase levels in the epidermis of patients with vitiligo. J. Invest. Dermatol., 1991, 97(6), 1081-1085.
98. Copple, I.M.; Goldring, C.E.; Kitteringham, N.R.; Park, B.K. The Nrf2-Keap1 defence pathway: role in protection against druginduced toxicity. Toxicology, 2008, 246(1), 24-33.
99. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82(1), 47-95.
100. Davies, K.J. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life, 1999, 48(1), 41-47.
101. Lee, Y.J.; Shacter, E. Hydrogen peroxide inhibits activation, not activity, of cellular caspase-3 in vivo. Free Radic. Biol. Med, 2000, 29(7), 684-692.
102. Chiarugi, P. From anchorage dependent proliferation to survival: lessons from redox signalling. IUBMB Life, 2008, 60(5), 301-307.
103. Brennan, M.; Bhatti, H.; Nerusu, K.C.; Bhagavathula, N.; Kang, S.; Fisher, G.J.; Varani, J.; Voorhees, J.J. Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen damage in UV-irradiated human skin. Photochem. Photobiol., 2003, 78(1), 43-48.
104. Shin, M.H.; Moon, Y.J.; Seo, J.E.; Lee, Y.; Kim, K.H.; Chung, J.H. Reactive oxygen species produced by NADPH oxidase, xanthine oxidase, and mitochondrial electron transport system mediate heat shock-induced MMP-1 and MMP-9 expression. Free Radic. Biol. Med., 2008, 44(4), 635-645.
105. Toyokuni, S.; Akatsuka, S. Pathological investigation of oxidative stress in the post-genomic era. Pathol. Int., 2007, 57(8), 461-473.
106. Bubici, C.; Papa, S.; Dean, K.; Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 2006, 25(51), 6731-6748.
107. Adachi, T.; Weisbrod, R.M.; Pimentel, D.R.; Ying, J.; Sharov, V.S.; Schöneich, C.; Cohen, R.A. (2004) S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat. Med., 2004, 10(11), 1200-1207.
108. Hool, L.C.; Corry, B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid. Redox Signal., 2007, 9(4), 409-435.
109. Basu, N.K.; Kole, L.; Basu, M.; Chakraborty, K.; Mitra, P.S.; Owens, I.S. The major chemical-detoxifying system of UDPglucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J. Biol. Chem., 2008, 283(34), 23048-23061.
110. Nagai, F.; Kato, E.; Tamura, H.O. Oxidative stress induces GSTP1 and CYP3A4 expression in the human erythroleukemia cell line, K562. Biol. Pharm. Bull., 2004, 27(4), 492-495.
111. Schisler, N.J.; Singh, S.M. Inheritance and expression of tissuespecific catalase activity during development and aging in mice. Genome, 1987, 29(5), 748-760.
112. Schrader, M.; Fahimi, H.D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta, 2006, 1763(12), 1755-1766.
113. Kirkman, H.N.; Gaetani, G.F. Catalase: a tetrameric enzyme with four tightly bound molecules of NADPH. Proc. Natl. Acad. Sci. USA, 1984, 81(14), 4343-4347.
114. Oshino, N.; Oshino, R.; Chance, B. The characteristics of the "peroxidatic" reaction of catalase in ethanol oxidation. Biochem. J., 1973, 131(3), 555-563.
115. Vetrano, A.M., Heck, D.E.; Mariano, T.M.; Mishin, V.; Laskin, D.L.; Laskin, J.D. Characterization of the oxidase activity in mammalian catalase, J. Biol. Chem., 2005, 280(42), 35372-35381.
116. Wood, J.M.; Gibbons, N.C.; Chavan, B.; Schallreuter, K.U. Computer simulation of heterogeneous single nucleotide polymorphisms in the catalase gene indicates structural changes in the enzyme active site, NADPH-binding and tetramerization domains: a genetic predisposition for an altered catalase in patients with vitiligo? Exp. Dermatol., 2008, 17(4), 366-371.
117. Kirkman, H.N.; Gaetani, G.F. Mammalian catalase: a venerable enzyme with new mysteries. Trends Biochem. Sci., 2007, 32(1), 44-50.
118. Reimer, D.L.; Bailley, J.; Singh, S.M. Complete cDNA and 5′ genomic sequences and multilevel regulation of the mouse catalase gene. Genomics, 1994, 21(2), 325-336.
119. Nakashima, H.; Yamamoto, M.; Goto, K.; Osumi, T.; Hashimoto, T.; Endo, H. Isolation and characterization of the rat catalaseencoding gene. Gene, 1989, 79(2), 279-288.
120. Góth, L.; Eaton, J.W. Hereditary catalase deficiencies and increased risk of diabetes. Lancet, 2000, 356(9252), 1820-1821. [122] Zachara, B.A. Mammalian selenoproteins. J. Trace Elem. Electrolytes Health Dis., 1992, 6(3), 137-151.
121. Brigelius-Flohé, R. Glutathione peroxidases and redox-regulated transcription factors. Biol. Chem., 2006, 387(10-11), 1329-1335.
122. Rhee, S.G.; Chae, H.Z.; Kim, K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signalling. Free Radic. Biol. Med., 2005, 38(12), 1543-1552.
123. Cha, M.K.; Suh, K.H.; Kim, I.H. Overexpression of peroxiredoxin I and thioredoxin 1 in human breast carcinoma. J. Exp. Clin. Cancer Res., 2009, 28(1), 93.
124. Zhang, B.; Wang, Y.; Su, Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett., 2009, 286(2), 154-160.
125. Kipen, H.M.; Fiedler, N. Environmental Factors in Medically Unexplained Symptoms and Related Syndromes: The Evidence and the Challenge. Environ. Health Perspect., 2002, 110(Suppl.4), 597-599.
126. Black, D.W.; Doebbeling, B.N.; Voelker, MD; Clarke, W.R.; Woolson, R.F.; Barrett, D.H.; Schwartz, D.A. Multiple Chemical Sensitivity Syndrome. Symptom Prevalence and Risk Factors in a Military Population. Arch. Int. Med., 2000, 160(8), 1169-1176.
127. Bornschein, S.; Förstl, H.; Zilker, T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J. Intern. Med., 2001, 250(4), 309-321.
128. Bailer, J.; Witthöft, M.; Paul, C.; Bayerl, C.; Rist, F. Evidence for overlap between idiopathic environmental intolerance and somatoform disorders. Psychosom. Med., 2005, 67(6), 921-929.
129. Bolt, H.M.; Kiesswetter, E. Is multiple chemical sensitivity a clinically defined entity? Toxicol. Lett., 2002, 128(1-3), 99-106.
130. Willette, A.A.; Lubach, G.R., Coe, C.L. Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey. Brain Behav. Immun., 2007, 21(6), 807-815.
131. Yadav, S.; Zajac, E.; Singhal, S.S.; Awasthi, S. Linking stresssignaling, glutathione metabolism, signaling pathways and xenobiotic transporters. Cancer Metastasis Rev., 2007, 26(1), 59-69.
132. Mattson, M.P.; Cheng, A. Neurohormetic phytochemicals: Lowdose toxins that induce adaptive neuronal stress responses. Trends Neurosci., 2006, 29(11), 632-639.
133. Wolfe, F.; Smythe, H.A.; Yunus, M.B.; Bennett, R.M.; Bombardier, C.; Goldenberg, D.L.; Tugwell, P.; Campbell, S.M.; Abeles, M.; Clark, P.; Fam, A.G.; Farber, S.J.; Fiechtner, J.J.; Michael Franklin, C.; Gatter, R.A.; Hamaty, D.; Lessard, J.; Lichtbroun, A.S.; Masi, A.T.; Mccain, G.A.; John Reynolds, W.; Thomas J.; Romano, I.; Russell, J.; Sheon, R.P. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum., 1990, 33(2), 160-172.
134. Buskila, D. Genetics of chronic pain states. Best Pract. Res. Clin. Rheumatol., 2007, 21(3), 535-547.
135. th ed.; Lippincott Williams and Wilkins: Philadelphia, 2008.
136. Sendur, O.F.; Turan, Y.; Tastaban, E.; Yenisey, C.; Serter, M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol. Int., 2009, 29(6), 629-633.
137. Lorusso, L.; Mikhaylova, S.V.; Capelli, E.; Ferrari, D.; Ngonga, G.K.; Ricevuti, G. Immunological aspects of chronic fatigue syndrome. Autoimmun. Rev., 2009, 8(4), 287-291.
138. Maes, M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr. Opin. Psychiatry, 2009, 22(1), 75-83.
139. Maes, M.; Mihaylova, I.; De Ruyter, M. Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J. Affect. Disord., 2006, 90(2-3), 141-147.
140. Lau, C.S.; Mak, A. The socioeconomic burden of SLE. Nat. Rev. Rheumatol., 2009, 5(7), 400-404.
141. McCarty, D.J.; Manzi, S.; Medsger, T.A. Jr; Ramsey-Goldman, R.; LaPorte, R.E.;Kwoh, C.K. Incidence of systemic lupus erythematosus. Race and gender differencies. Arthritis Rheum., 1995, 38(9), 1260-1270.
142. Fessel, W.J. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch. Intern. Med., 1974, 134(7), 1027-1035.
143. Reichlin, M.; Harley, J.B.; Lockshin, M.D. Serologic studies of monozygotic twins with systemic lupus erythematosus. Arthritis Rheum., 1992, 35(4), 457-464.
144. Kelly, J.A.; Moser, K.L.; Harley, J.B. The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun., 2002, 3(Suppl. 1), S71-S85.
145. Nath, S.K.; Namjou, B.; Garriott, C.P.; Frank, S.; Joslin, P.A.; Kilpatrick J.; Keely, J.A.; Harley, J.B. Linkage analysis of SLE susceptibility: confirmation of SLER1 at 5p15.3. Genes Immun., 2004, 5(3), 209-214.
146. Karlson, E.W.; Watts, J.; Singorovitch, J.; Bonetti, M.; Wright, E.; Cooper, G.S.; McAlindon, T.E.; Costenbader, K.H.; Massarotti, E.M.; Fitzgerald, L.M.; Jajoo, R.; Husni, M.E.; Fossel, A.H.; Pankey, H.; Ding, W.Z.; Knorr, R.; Condon, S.; Fraser, P.A. Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury lupus project. Arthritis Rheum., 2007, 56(1), 244-254.
147. Wallace, D.J.; Quismorio, F.P. Jr. The elusive search for geographic clusters of systemic lupus erythematosus: critical review. Arthritis Rheum., 1995, 38(11), 1564-1567.
148. Balluz, L.; Philen, R.; Ortega, L.; Rosales, C.; Brock, J.; Barr, D.; Kiezak S. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am. J. Epidemiol., 2001, 154(11), 1029-1036.
149. Sarzi-Puttini, P.; Atzeni, F.; Capsoni, F.; Lubrano, E.; Doria, A. Drug-induced lupus erythematosus. Autoimmunity, 2005, 38(7), 507-518.
150. Alkhateeb, A.; Fain, P.R.; Thody, A.; Bennett, D.C.; Spritz, R.A. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res., 2003, 16(3), 208-214.
151. Spritz, R.A. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res., 2007, 20(4), 271-278.
152. Strömberg, S.; Björklund, M.G.; Asplund, A.; Rimini, R.; Lundeberg, J.; Nilsson, P.; Pontén, F.; Olsson, M.J. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris. Pigment Cell Melanoma Res., 2008, 21(2), 162-171.
153. Casp, C.B.; She, J.X.; McCormack, W.T. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res., 2002, 15(1), 62-66.
154. Jin, S.Y.; Park, H.H.; Li, G.Z.; Lee H.J.; Hong, M.S., Park, H.J., Park, H.K., Seo, J.C., Yim, S.V., Chung, J.H., Lee, M.H. Association of estrogen receptor 1 intron 1 C/T polymorphism in Korean vitiligo patients. J. Dermatol. Sci., 2004, 35(3), 181-186.
155. Uhm, Y.K.; Yoon, S.H.; Kang, I.J.; Chung, J.H.; Yim, S.V; Lee, M.H. Association of glutathione S-transferase gene polymorphisms (GSTM1 and GSTT1) of vitiligo in Korean population. Life Sci. 2007, 81(3), 223-227.
156. Tursen, U.; Kaya, T.I.; Erdal, M.E.; Derici, E.; Gunduz, O.; Ikizoglu, G. Association between catechol-O-methyltransferase polymorphism and vitiligo. Arch. Dermatol. Res., 2002, 294(3), 143-146.
157. Agrawal, D.; Shajil, E.M.; Marfatia, Y.S.; Begum, R. Study on antioxidant status of vitiligo patients of different age groups in Baroda. Pigment Cell Res., 2004, 17(3), 289-294.
158. Em, S.; Laddha, N.C.; Chatterjee, S.; Gani, A.R.; Malek, R.A.; Shah, B.J.; Begum, R. Association of catalase T/C exon 9 and glutathione peroxidase
159. Schallreuter, K.U.; Bahadoran, P.; Picardo, M.; Slominski, A.; Elassiuty, Y.E.; Kemp, E.H.; Giachino, C.; Liu, J.B.; Luiten, R.M.; Lambe, T.; Le Poole, I.C.; Dammak, I.; Onay, H.; Zmijewski, M.A.; Dell'Anna, M.L.; Zeegers, M.P.; Cornall, R.J.; Paus, R.; Ortonne, J.P.; Westerhof, W. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp. Dermatol., 2008, 17(2), 139-160.
160. Nerbert, D.W. Role of genetics and drug metabolism in human cancer risk. Mutat. Res., 1991, 247(2), 267-281.
161. Rannug, A.; Alexandrie, A.K.; Persson, I.; Ingelman-Sundberg, M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J. Occup. Environ. Med., 1995, 37(1), 25-36.
162. McKeown-Eyssen, G.; Baines, C.; Cole, D.E.; Riley, N.; Tyndale, R.F.; Marshall, L.; Jazmaji, V. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int. J. Epidemiol., 2004, 33(5), 971-978.
163. Schnakenberg, E.; Fabig, K.R.; Stanulla, M.; Strobl, N.; Lustig, M.; Fabig, N.; Schloot, W. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environ. Health, 2007, 6, 6.
164. Wiesmüller, G.A.; Niggemann, H.; Weissbach, W.; Riley, F.; Maarouf, Z.; Dott, W.; Kunert, H.J.; Zerres, K.; Eggermann, T.; Blömeke, B. Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): a case-control study. J. Toxicol. Environ. Health A, 2008, 71(11-12), 786-794.
165. Skeith, K.J.; Hussain, M.S.; Coutts, R.T.; Ramos-Remus, C.; Avina-Zubieta, J.A., Russell, A.S. Adverse drug reactions and debrisoquine/ sparteine (P450IID6) polymorphism in patients with fibromyalgia. Clin. Rheumatol., 1997, 16(3), 291-295.
166. Kortunay, S.; Bozkurt, A.; Bathum, L.; Basci, N.E.; Calgüneri, M.; Brøsen, K.; Kayaalp, S.O. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann. Rheum. Dis., 1999, 58(3), 182-185.
167. Kortunay, S.; Bozkurt, A.; Bathum, L.; Basci, N.E.; Calgüneri, M.; Brøsen, K.; Kayaalp, S.O. CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur. J. Clin. Pharmacol., 1999, 55(1), 21-25.
168. Takada, K.; Arefayene, M.; Desta, Z.; Yarboro, C.H.; Boumpas, D.T.; Balow, J.E.; Flockhart, D.A.; Illei, G.G. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum., 2004, 50(7), 2202-2210.
169. Strange, R.C.; Fryer, A.A. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci. Publ., 1999, 148, 231-249.
170. Tew, K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., 1994, 54(16), 4313-4320.
171. Kang, T.Y.; El-Sohemy, A.; Comelis, M.C.; Eny, K.M.; Bae, S.C. Glutathione S-transferase genotype and risk of systemic lupus erythematosus in Koreans. Lupus, 2005, 14(5), 381-384.
172. Fraser, P.A.; Ding, W.Z.; Mohseni, M.; Treadwell, E.L.; Dooley, M.A.; St Clair, E.W.; Gilkeson, G.S.; Cooper, G.S. Glutathione Stransferase M null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible geneenvironment interaction for autoimmunity. J. Rheumatol., 2003, 30(2), 276-282.
173. Zhong, S.; Huang, M.; Yang, X.; Liang, L.; Wang, Y.; Romkes, M.; Duan, W.; Chan, E.; Zhou, S. F. Relationship of glutathione Stransferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br. J. Clin. Pharmacol., 2006, 62(4), 457-472.
174. Nielsen, P. S.; Okkels, H.; Sigsgaard, T.; Kyrtopoulos, S.; Autrup, H. Exposure to urban and rural air pollution: DNA and protein ad ducts and effect of glutathione-S-transferase genotype on adduct levels. Int. Arch. Occup. Environ. Health., 1996, 68(3),170-176.
175. Yun, B.R.; El-Sohemy, A.; Cornelis, M.C.; Bae, S.C. Glutathione S-transferase M1, T1, and P1 genotypes and rheumatoid arthritis. J. Rheumatol., 2005, 32(6), 992-997.
176. Li, Y.; Yang, X.; van Breemen, R.B.; Bolton, J.L. Characterization of two new variants of human catechol O-methyltransferase in vitro. Cancer Lett., 2005, 230(1), 81-89.
177. Mannisto, P.T.; Kaakkola, S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 1999, 51(4), 593-628.
178. Watanabe, M.; Harada, S.; Nakamura, T.; Ohkoshi, N.; Yoshizawa, K.; Hayashi, A.; Shoji, S. Association between catechol-Omethyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology, 2003, 48(4), 190-193.
179. Xu, H.; Kellendonk, C.B.; Simpson, E.H.; Keilp, J.G.; Bruder, G.E.; Polan, H.J.; Kandel, E.R.; Gilliam, T.C. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr. Res., 2007, 90(1-3), 104-107.
180. Domschke, K.; Freitag, C.M.; Kuhlenbäumer, G.; Schirmacher, A.; Sand, P.; Nyhuis, P.; Jacob, C.; Fritze, J.; Franke, P.; Rietschel, M.; Garritsen, H.S.; Fimmers, R.; Nöthen, M.M.; Lesch, K.P.; Stögbauer, F.; Deckert, J. Association of the functional V158M catechol-O-methyl- transferase polymorphism with panic disorder in women. Int. J. Neuropsychopharmacol., 2004, 7(2), 183-138.
181. Diatchenko, L.; Slade, G.D.; Nackley, A.G.; Bkalang, K.; Sigurdsson, A.; Belfer, I., Goldman, D.; Xu, K., Shabalina, S.A.; Shagin, D. Genetic basis and individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet., 2005, 14(1), 135-143.
182. Tchivileva, I.E.; Nackley, A.G.; Qian, L.; Wentworth, S.; Conrad, M.; Diatchenko, L.B. Characterization of NF-kB-mediated inhibition of catechol-O-methyl transferase. Mol. Pain, 2009, 5, 13.
183. Chan, C.F.; Sun, W.Z., Lin, J.K.; Lin-Shiau, S.Y. Activation of transcription factors of nuclear factor kappa b, activator protein-I and octamer factor in hyperalgesia. Eur. J. Pharmacol., 2000, 402(1-2), 61-68.
184. George, S.Z.; Dover, G.C.; Wallace, M.R.; Sack, B.K.; Herbstman, D.M.; Aydog, E; Fillingim, R.B. Biopsychosocial influence on exercise-induced delayed onset muscle soreness at the shoulder: pain catastrophizing and catechol-o-methyltransferase (COMT) diplotype predict pain ratings. Clin. J. Pain, 2008, 24(9), 793-801.
185. Goertzel, B.N.; Pennachin, C.; de Souza Coelho, L.; Gurbaxani, B.; Maloney, E.M.; Jones, J.F. Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics, 2006, 7(3), 475-483.
186. Li, K.; Li, C.; Gao, L.; Yang, L.; Li, M.; Liu, L.; Zhang, Z.; Liu, Y.; Gao, T. A functional single-nucleotide polymorphism in the catechol-O- methyltransferase gene alter vitiligo risk in a Chinese population. Arch. Dermatol. Res., 2009, 301(9), 681-687.
187. Le Poole, I.C.; van den Wijngaard, R.M.; Smit, N.P.; Oosting, J.; Westerhof, W.; Pavel, S. Catechol-O-methyltransferase in vitiligo. Arch. Dermatol Res., 1994, 286(2), 81-86.
188. Morrone, A.; Picardo, M.; De Luca, C.; Terminali, O.; Passi, S.; Ippolito, F. Catecholamines and vitiligo. Pigm. Cell Res., 1992, 5(2), 65-69.
189. Miners, J.O.; McKinnon, R.A.; Mackenzie, P.I. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology, 2002, 181-182, 453-456.
190. Peters, W.H.M.; te Morsche, R.H.M.; Roelofs, H.M.J. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J. Hepatol., 2003, 38(1), 3-8.
191. van der Heide, S.M.; Joosten, B.J.L.J.; Everts, M.E.; Klaren, P.H.M. Activities of UDP-glucuronyltransferase, -glucuronidase and deiodinase types I and II in hyper- and hypothyroid rats. J. Endocrinol., 2004, 181(3), 393-400.
192. Appenzeller, S.; Pallone, A.T.; Natalin, R.A.; Costallat, L.T. Prevalence of thyroid dysfunction in systemic lupus erythematosus. Clin Rheumatol., 2009, 5(3), 117-119.
193. Baines, C.J.; McKeown-Eyssen, G.E.; Riley, N.; Cole, D.E.C.; Marshall, L.; Loescher, B.; Jazmaji, V. Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures. Occup. Med., 2004, 54(6), 408-418.
194. Gulseren, S.; Gulseren, L.; Hekimsoy, Z.; Cetinay, P.; Ozen, C.; Tokatlioglu, B. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction (2006) Arch. Med. Res., 37(1), 133-139.
195. Eis, D.; Helm, D.; Mühlinghaus, T.; Birkner, N.; Dietel, A.; Eikmann, T.; Gieler, U.; Herr, C.; Lacour, M.; Nowak, D.; Pedrosa Gil, F.; Podoll, K.; Renner, B.; Andreas Wiesmüller, G.; Worm, M. The German Multicentre Study on Multiple Chemical Sensitivity (MCS). Int. J. Hyg. Environ. Health, 2008, 211(5-6), 658-681.
196. Wiesmüller, G.A., Niggemann, H.; Weissbach, W., Riley, F., Maarouf, Z., Dott, W.; Kunert, H.J.; Zerres, K., Eggermann, T.; Blömeke, B. Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): a case-control study. J. Toxicol. Environ. Health A, 2008, 71(11-12), 786-794.
197. Ogata, M.; Wang, D.H.; Ogino, K. Mammalian acatalasemia: the perspectives of bioinformatics and genetic toxicology. Acta Med. Okayama, 2008, 62(6), 345-361.
198. Terlecky, S.R.; Koepke, J.I.; Walton, P.A. Peroxisomes and aging. Biochim. Biophys. Acta, 2006, 1763(12), 1749-1754.
199. Wood, C.S.; Koepke J.I.; Teng H.; Boucher K.K.; Katz S.; Chang P.; Terlecky L.J.; Papanayotou I.; Walton, P.A.; Terlecky, S.R. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic, 2006, 7(1), 97-107.
200. Gavalas, N.G.; Akhtar, S.; Gawkrodger, D.J.; Watson, P.F.; Weetman, A.P.; Kemp, E.H. Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. Biochem. Biophys. Res. Commun., 2006, 345(4), 1586-1591.
201. Park, H.H.; Ha, E.; Uhm, Y.K.; Jin, S.Y.; Kim, Y.J.; Chung, J.H.; Lee, M.H. Association study between catalase gene polymorphisms and the susceptibility to vitiligo in Korean population. Exp. Dermatol., 2006, 15(5), 377-380.
202. Shajil, E.M.; Laddha, N.C.; Chattetjee, S.; Gani, A.R.; Malek, R.A.; Shan, B.J.; Begum, R. Association of catalase T/C exon 9 and glutathione peroxidase codon 200 polymorphisms in relation to their activities and oxidative stress with vitiligo susceptibility in Gujarat population. Pigment Cell Res., 2007, 20(5), 405-407.
203. Gibbons, N.C.; Wood, J.M.; Rokos, H.; Schallreuter, K.U. Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J. Invest. Dermatol., 2006, 126(12), 2576-2582.
204. Westerhof, W.; d'Ischia, M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res., 2007, 20(5), 345-359.
205. Dell'anna, M.L.; Picardo, M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res., 2006, 19(5), 406-411.
206. Eny, K.M.; El-Sohemy, A.; Cornelis, M.C.; Sung, Y.-K.; Bae, S.C. Catalase and PPARgamma2 genotype and risk of systemic lupus erythematosus in Koreans. Lupus, 2005, 14(5), 351-355.
207. Warchol, T.; Lianeri, M.; Wudarski, M.; Łacki, J.K.; Jagodzinski, P.P. Catalase -262C>T polymorphism in systemic lupus erythematosus in Poland. Rheumatol. Int., 2008, 28(10), 1035-1039.
208. Smith-Pearson, P.S.; Kooshki, M.; Spitz, D.R.; Poole, L.B.; Zhao, W.; Robbins, M.E. Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H2O2. Free Radic. Biol. Med., 2008, 45(8), 1178-1189.
209. Brigelius-Flohé, R.; Kipp, A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta., 2009, 1790(11), 1555-1568.
210. Khan, R.; Satyam, A.; Gupta, S.; Sharma, V.K.; Sharma, A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch. Dermatol. Res., 2009, 301, 731-737.
211. Dammak, I.; Boudaya, S.; Ben Abdullah, F.; Turki, H.; Attia, H.; Hentati, B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int. J. Dermatol., 2009, 48(5), 476-480.
212. Yildirim, M.; Baysal, V.; Inaloz, H.S.; Kesici, D.; Delibas, N. The role of oxidants and antioxidants in generalized vitiligo. J. Dermatol., 2003, 30(2), 104-108.
213. Beazley, W.D.; Gaze, D.; Panske, A.; Panzig, E.; Schallreuter, K.U. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br. J. Dermatol., 1999, 141(2), 301-303.
214. Hazneci, E.; Karabulut, A.B.; Oztürk, C.; Batçioǧlu, K.; Doǧan, G.; Karaca, S.; Eşrefoǧlu, M. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int. J. Dermatol., 2005, 44(8), 636-640.
215. Huang, W.N.; Tso, T.K.; Huang, H.Y. Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus. Rheumatol. Int., 2007, 27(5), 453-458.
216. Bae, S.C.; Kim, S.J.; Sung, M.K. Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatol. Int., 2002, 22(6), 238-243.
217. Taysi, S.; Gul, M.; Sari, R.A.; Akcay, F.; Bakan, N. Serum oxidant/ antioxidant status of patients with systemic lupus erythematosus. Clin. Chem. Lab. Med., 2002, 40(7), 684-688.
218. Fulle, S.; Mecocci, P.; Fano, G.; Vecchiet, I.; Vecchini, A.; Ricciotti, D.; Cherubini, A.; Pizzigallo, E.; Vecchiet, L.; Senin, U.; Beal, M.F. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic. Biol. Med., 2000, 29(12), 1252-1259.
219. Karasawa, R.; Ozaki, S.; Nishioka, K.; Kato, T. Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol. Immunol., 2005, 49(1), 57-65.
220. Iwata, Y.; Ogawa, F.; Komura, K.; Muroi, E.; Hara, T.; Shimizu, K.; Hasegawa, M.; Fujimoto, M.; Tomita, Y.; Sato, S. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology (Oxford), 2007, 46(5), 790-795.
221. Kennedy, G.; Spence, V.A.; McLaren, M.; Hill, A.; Underwood, C.; Belch, J.J. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic. Biol. Med., 2005, 39(5), 584-589.
222. Pall, M.L. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypotheses, 2000, 54(1), 115-125.
223. Vecchiet, J.; Cipollone, F.; Falasca,K.; Mezzetti, A.; Pizzigallo, E.; Bucciarelli, T.; De Laurentis, S.; Affaitati, G.; De Cesare, D.; Giamberardino, M.A. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci. Lett., 2003, 335(3), 151-154.
224. Radi, R.; Rodriguez, M.; Castro, L.; Telleri, R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch. Biochem. Biophys., 1994, 308(1), 89-95.
225. Richards, R.S.; Wang, L.; Jelinek, H. Erythrocyte oxidative damage in chronic fatigue syndrome. Arch. Med. Res., 2007, 38(1), 94-98.
226. Smirnova, I.V.; Pall, M.L. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol. Cell Biochem., 2003, 248(1-2), 93-95.
227. Miwa, K.; Fujita, M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int. J. Cardiol., 2009, 136(2), 238-239.
228. Aoki, T.; Miyakoshi, H.; Usuda, Y.; Herberman, R.B. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin. Immunol. Immunopathol., 1993, 69(3), 253-265.
229. Cordero, M.D.; Moreno-Fernandez, A.M.; deMiguel, M.; Bonal, P.; Campa, F.; Jimenez-Jimenez L.M.; Ruiz-Losada, A.; Sanches-Dominques, B.; Sanchez Alcazar, J.A.; Salviati, L.; Navas, P. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin. Biochem., 2009, 42(7-8), 732-735.
230. Kaufmann, I.; Schelling, G.; Eisner, C.; Richter, H.P.; Krauseneck, T.; Vogeser, M.; Hauer, D.; Campolongo, P.; Chouker, A.; Beyer, A.; Thiel, M. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology, 2008, 33(5), 676-685.
231. Eisinger, J.; Zakarian, H.; Pouly, E.; Planatmura, A.; Ayavou, T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnes. Res., 1996, 9(4), 313-316.
232. Bagis, S.; Tamer, L.; Sahin, G.; Bilgin, R.; Guler H.; Ercan, B.; Erdogan, C. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol. Int., 2005, 25(3), 188-190.
233. Schallreuter KU. Effectiveness of pseudocatalase formulations in vitiligo. Clin. Exp. Dermatol., 2003, 28(5), 562-263.